



Piramal Healthcare Ltd


Q3FY11 Result Summary

Rs mn	Q3FY11	Q2FY11	Q3FY10	q-o-q (%)	y-o-y (%)
Net Sales	4027	7520	9077	-46	-56
Raw Material Cost	1764	2956	3438	-40	-49
Employees cost	981	1633	1416	-40	-31
Other expenses	1608	3185	2449	-50	-34
EBITDA	1142	-51	1807	2338	-37
EBITDA margin	28	-1	20	2900bps	840bps
Depreciation	240	318	434	-25	-45
EBIT	901	-369	1373	344	-34
Interest and finance charges	129	29	217	349	-40
PBT	772	161842	1157	-100	-33
Tax	169	36439	-204	-100	182
PAT	603	125404	1361	-100	-56
PAT Margin (%)	15	1668	15	-165260bps	0bps
No of equity shares (Mn)	209	209	209		
EPS (Rs)	2.90	600.00	6.50	-99.52	-55.38


The company's top-line declined by 56% in Q3FY11 on y-o-y basis largely on account of pharmaceuticals revenue which declined by ~53% on y-o-y basis.

EBITDA margins improved by ~800 bps mainly on account of forex gain of Rs 145 mn and decrease in raw material and employee costs.


Revenue and EBITDA margins




PAT and PAT margins



Share price movement



Shareholding pattern



Additional Disclosure

This report has been sponsored by NSE - Investor Protection Fund Trust (NSEIPFT).

Disclaimer

This report is based on data publicly available or from sources considered reliable. CRISIL Ltd. (CRISIL) does not represent that it is accurate or complete and hence, it should not be relied upon as such. The data / report is subject to change without any prior notice. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The subscriber / user assume the entire risk of any use made of this data / report. CRISIL especially states that, it has no financial liability whatsoever, to the subscribers / users of this report. This report is for the personal information only of the authorised recipient in India only. This report should not be reproduced or redistributed or communicated directly or indirectly in any form to any other person – especially outside India or published or copied in whole or in part, for any purpose.

CRISIL is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of this report. For information please contact 'Client Servicing' at +91-22-33423561, or via e-mail: clientservicing@crisil.com.